Article about Gene and Cell Therapy

June 8, 2021
Download attachmentRead full press release on Cision (external link)
2024-02-27
NextCell Pharma’s updated growth strategy
NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company has decided to implement strategic changes. The new strategic direction means, amongst other things, that Cellaviva will become a wholly owned subsidiary and that the company's GMP facility will have new sources of revenue. The strategic changes will also result in cost savings as a result of staff reduction.
Read moreRead more
2024-02-14
NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy
Today Wednesday on February 14th at 10.30 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the"Company"), will present the latest developments in the company at Redeye.
Read moreRead more
2024-01-25
NextCell publishes its Interim Report 1 2023/2024
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2023 – November 30, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  
Read moreRead more
2024-01-24
Updates regarding NextCell’s Clinical Trials with ProTrans
NextCell Pharma has several ongoing clinical trials with ProTrans. The largest ongoing study ProTrans Young, which includes 66 patients, is progressing well. All 30 patients in the older age group have been recruited and will be treated with ProTrans. In the long-term follow-up studies ProTrans-Obs and ProTrans-Repeat the first diabetes patients have now completed the studies after five years of follow-up.
Read moreRead more
2023-12-13
NextCell Pharma has compiled a Q&A section
NextCell Pharma AB ("NextCell" or the "Company") has compiled questions from the company’s stakeholders in a Q&A section. The questions and answers can be accessed via the link below.
Read moreRead more
2023-11-06
Repeated treatment with ProTrans is immunologically safe
NextCell Pharma AB ("NextCell" or the "Company") today announces that multiple treatments with ProTrans cell therapy does not induce donor specific antibodies in type-1 diabetes patients. A detailed analysis of how the immune system reacts to infusion of ProTrans cells show that treatment can be given to any adult type 1 diabetic, irrespective of pre-existing HLA antibodies.
Read moreRead more
2023-10-26
NextCell publishes its Year-End Report 2022/2023
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2022 – August 31, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  
Read moreRead more
2023-10-10
NextCell signs an agreement for a new tissue product
NextCell Pharma AB (“NextCell” or “the company”) announces that the company has signed an agreement with the Finnish biotechnology company Linio to warehouse and distribute Tience® in Sweden. The value of the agreement for the first year amounts to approximately 400 000 SEK in fixed remuneration and a variable remuneration per product delivered. Tience is a tissue product that is injected to combat scarring and can also be used for aesthetic purposes such as skin rejuvenation and to combat wrinkles. The product is marketed and sold by Linio to clinics and hospitals.
Read moreRead more